Unicycive Therapeutics’ (UNCY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCYFree Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $4.50 target price on the stock.

Several other brokerages have also issued reports on UNCY. Piper Sandler assumed coverage on Unicycive Therapeutics in a report on Thursday, April 4th. They set an overweight rating and a $9.00 price target for the company. Noble Financial assumed coverage on Unicycive Therapeutics in a report on Wednesday, February 14th. They set an outperform rating and a $6.00 price target for the company. Finally, Benchmark reiterated a speculative buy rating and set a $3.00 price target on shares of Unicycive Therapeutics in a report on Monday, April 15th.

Get Our Latest Stock Report on UNCY

Unicycive Therapeutics Trading Up 5.2 %

Shares of NASDAQ UNCY opened at $0.88 on Wednesday. Unicycive Therapeutics has a one year low of $0.47 and a one year high of $1.82. The firm has a market capitalization of $33.10 million, a PE ratio of -0.74 and a beta of 2.72. The business has a 50-day moving average price of $1.15 and a two-hundred day moving average price of $1.04.

Unicycive Therapeutics (NASDAQ:UNCYGet Free Report) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. Research analysts anticipate that Unicycive Therapeutics will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in shares of Unicycive Therapeutics in the 1st quarter valued at approximately $36,000. BVF Inc. IL raised its stake in shares of Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after acquiring an additional 1,493,462 shares in the last quarter. Rosalind Advisors Inc. bought a new position in shares of Unicycive Therapeutics in the 1st quarter valued at approximately $2,594,000. Vivo Capital LLC bought a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at approximately $2,984,000. Finally, RA Capital Management L.P. bought a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at approximately $2,985,000. 40.42% of the stock is owned by institutional investors.

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

Featured Stories

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.